Does low triiodothyronine (T3) signaling raise LDL cholesterol and ApoB by reducing hepatic LDL receptor expression and activity?

The regulation of cholesterol metabolism is deeply integrated with thyroid hormone signaling. Triiodothyronine (T3) serves as a master metabolic regulator that maintains lipid homeostasis by controlling the expression and activity of the hepatic low-density lipoprotein receptor (LDLR).

Clinical and effectiveness evidence

Research consistently demonstrates that low T3 signaling is a primary driver of dyslipidemia.

• LDL Fractional Catabolic Rate (FCR): Human tracer studies show that low thyroid function significantly reduces the LDL FCR, which measures the rate of LDL removal from the blood. In hypothyroid states, this clearance rate can drop by 30-50%, leading to a direct increase in serum LDL cholesterol.
• Apolipoprotein B (ApoB): Each atherogenic particle (VLDL, IDL, and LDL) carries exactly one molecule of ApoB. Evidence from kinetic studies indicates that reduced LDLR-mediated clearance leads to a stoichiometric increase in circulating ApoB particles, as they remain in the bloodstream for longer periods.
• Treatment Response: Meta-analyses of levothyroxine (T4) replacement therapy, which the body converts to T3, show that normalizing thyroid signaling improves LDL receptor activity and lowers LDL-C and ApoB levels, confirming the causal link between T3 signaling and lipid clearance.

Mechanistic explanations

T3 influences the LDL receptor through two primary molecular pathways in the liver:

• Direct Transcriptional Control: T3 enters hepatocytes and binds to thyroid hormone receptors (primarily TRβ), which then bind to the promoter region of the LDLR gene to directly stimulate its transcription.
• Indirect SREBP2 Pathway: T3 increases the expression of enzymes like CYP7A1, which convert cholesterol into bile acids. This depletion of hepatic cholesterol triggers the activation and nuclear translocation of Sterol Regulatory Element-Binding Protein 2 (SREBP2). SREBP2 then binds to sterol response elements in the LDLR promoter, further amplifying receptor expression.
• Clearance Mechanism: Once expressed on the hepatocyte surface, the LDLR binds to ApoB-containing particles, facilitating their removal via clathrin-dependent endocytosis. Low T3 signaling disrupts both the production and activity of these receptors, leading to reduced hepatic uptake of LDL.

Practical implications

• Subclinical Hypothyroidism: Even mild reductions in thyroid signaling (subclinical hypothyroidism) have been shown to elevate ApoB and LDL-C levels, suggesting that thyroid status should be evaluated in patients with unexplained hyperlipidemia.
• Cardiovascular Risk: Because low T3 signaling increases the residence time and concentration of ApoB-containing particles, it contributes to an increased risk of atherosclerosis.

Bottom line

Low T3 signaling reduces both the transcription and activity of hepatic LDL receptors through direct genomic effects and the SREBP2 pathway. This impairment reduces the rate of LDL clearance, leading to a significant accumulation of LDL cholesterol and atherogenic ApoB-containing particles in the circulation.